Compare ACNB & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACNB | PRLD |
|---|---|---|
| Founded | 1857 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 659.3M | 529.1M |
| IPO Year | 1994 | 2020 |
| Metric | ACNB | PRLD |
|---|---|---|
| Price | $62.89 | $3.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $67.67 | $9.20 |
| AVG Volume (30 Days) | 43.8K | ★ 395.6K |
| Earning Date | 10-22-2026 | 11-11-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ 2.81 | N/A |
| Revenue | ★ $191,821,000.00 | $12,140,000.00 |
| Revenue This Year | $11.18 | $258.83 |
| Revenue Next Year | $2.91 | N/A |
| P/E Ratio | $22.35 | ★ N/A |
| Revenue Growth | 45.10 | ★ 73.43 |
| 52 Week Low | $42.60 | $1.15 |
| 52 Week High | $67.60 | $6.83 |
| Indicator | ACNB | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 32.49 |
| Support Level | $51.44 | $3.40 |
| Resistance Level | $65.62 | $4.10 |
| Average True Range (ATR) | 1.29 | 0.28 |
| MACD | -0.29 | -0.08 |
| Stochastic Oscillator | 12.78 | 11.76 |
ACNB Corp is the financial holding company. Through its wholly-owned subsidiaries, it provides a full range of retail and commercial financial services in Pennsylvania and Maryland through its network of community banking offices. It also provides property, casualty, health, life and disability insurance serving personal and commercial clients through offices in Westminster, Maryland, and Gettysburg, Pennsylvania and is licensed to do business. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage; and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.